GSK thinks small as part of new R&D approach

07/1/2010 | Wall Street Journal, The

GlaxoSmithKline is breaking up its research-and-development team into smaller, more specialized groups in an effort to bypass the bureaucracy that has hampered it from producing many new drugs over the past decade. GSK hopes these groups will imitate the success of smaller biotech companies. However, some analysts have questioned the approach. "The problem with big companies trying to act like biotechs is that people who like the really entrepreneurial culture of a biotech go to biotechs," one health care analyst said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN